Oric Pharmaceuticals, Inc.
ORICNasdaq
$10.73
0.0%Jul 17 close · end-of-day
Price
1Y↓ -4.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.1B
Enterprise Value
$849.8M
P/E
—
P/S
—
P/B
2.7
EV/EBITDA
—
PEG
—
FCF Yield
-9.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$135.2M
Free Cash Flow (TTM)
-$111.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-32.5%
ROIC
-88.6%
Debt / Equity
—
Net Cash
$281.9M
Return 1Y
-3.7%
Company profile
ORIC Pharmaceuticals, Inc. discovers and develops therapies for treatment of cancers. Its product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
- CEO
- Jacob M. Chacko
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- California
- Website
- oricpharma.com
Management & directors
- Piscitelli DominicChief Financial Officer
- Chacko JacobPRESIDENT AND CEO
- Multani Pratik SChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
ORIC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.34↓ -19.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$74.2M | -$78.9M | -$91.8M | -$110.8M | -$142.9M | -$143.0M |
| Net income | -$73.7M | -$78.7M | -$89.1M | -$100.7M | -$127.8M | -$129.5M |
| Diluted EPS | — | -$2.07 | -$2.25 | -$1.96 | -$1.83 | -$1.47 |
| Operating cash flow | -$45.3M | -$59.5M | -$75.1M | -$85.7M | -$112.7M | -$111.0M |
| Free cash flow | -$45.9M | -$60.5M | -$77.2M | -$86.5M | -$113.8M | -$111.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$36.0M | -$38.3M | -$39.6M | -$32.7M | -$39.1M | -$36.7M | -$34.6M | -$39.6M |
| Net income | -$32.0M | -$34.6M | -$36.3M | -$30.0M | -$36.4M | -$32.6M | -$30.5M | -$35.8M |
| Diluted EPS | -$0.45 | -$0.49 | -$0.52 | -$0.42 | -$0.47 | -$0.33 | -$0.25 | -$0.34 |
| Operating cash flow | -$25.6M | -$28.8M | -$28.1M | -$32.5M | -$30.8M | -$25.1M | -$22.5M | -$32.4M |
| Free cash flow | -$26.0M | -$29.2M | -$28.3M | -$32.9M | -$30.9M | -$25.1M | -$22.7M | -$32.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Heyman Richard A. | Sale | 300 | $12.00 | $3,600.00 | filing |
| 2026-02-24 | Piscitelli Dominic· Chief Financial Officer | Sale | 52,000 | $13.51 | $702,686.40 | filing |
| 2026-02-24 | Piscitelli Dominic· Chief Financial Officer | Option exercise | 52,000 | $4.36 | $226,720.00 | filing |
| 2026-01-16 | Heyman Richard A. | Sale | 3,500 | $12.00 | $42,016.10 | filing |
| 2026-01-16 | Heyman Richard A. | Sale | 3,200 | $12.00 | $38,414.72 | filing |
| 2025-12-16 | Chacko Jacob· PRESIDENT AND CEO | Sale | 33,374 | $9.06 | $302,368.44 | filing |
| 2025-12-16 | Multani Pratik S· Chief Medical Officer | Sale | 10,720 | $9.06 | $97,128.56 | filing |
| 2025-12-16 | Piscitelli Dominic· Chief Financial Officer | Sale | 10,720 | $9.06 | $97,127.49 | filing |
| 2025-12-15 | Multani Pratik S· Chief Medical Officer | Option exercise | 29,333 | $0.00 | $0.00 | filing |
| 2025-12-15 | Piscitelli Dominic· Chief Financial Officer | Option exercise | 29,333 | $0.00 | $0.00 | filing |
| 2025-12-15 | Chacko Jacob· PRESIDENT AND CEO | Option exercise | 83,666 | $0.00 | $0.00 | filing |
| 2025-12-08 | Kunkel Lori Anne | Option exercise | 10,000 | $7.90 | $79,000.00 | filing |
| 2025-12-04 | Kunkel Lori Anne | Option exercise | 5,534 | $3.75 | $20,752.50 | filing |
| 2025-10-06 | Chacko Jacob· PRESIDENT AND CEO | Sale | 37,461 | $12.32 | $461,519.52 | filing |
| 2025-10-06 | Piscitelli Dominic· Chief Financial Officer | Sale | 11,000 | $14.52 | $159,718.90 | filing |
| 2025-10-06 | Piscitelli Dominic· Chief Financial Officer | Option exercise | 11,000 | $4.36 | $47,960.00 | filing |
| 2025-10-03 | Heyman Richard A. | Option exercise | 31,353 | $1.60 | $50,164.80 | filing |
| 2025-10-03 | Heyman Richard A. | Option exercise | 1,447 | $3.75 | $5,426.25 | filing |
| 2025-10-01 | Chacko Jacob· PRESIDENT AND CEO | Sale | 53,001 | $12.05 | $638,805.15 | filing |
| 2025-09-30 | Chacko Jacob· PRESIDENT AND CEO | Sale | 34,538 | $12.01 | $414,749.57 | filing |
| 2025-09-22 | Chacko Jacob· PRESIDENT AND CEO | Sale | 125,000 | $10.80 | $1.3M | filing |
| 2025-07-01 | Piscitelli Dominic· Chief Financial Officer | Sale | 20,000 | $10.05 | $200,972.00 | filing |
| 2025-06-24 | Piscitelli Dominic· Chief Financial Officer | Sale | 32,466 | $10.50 | $341,039.10 | filing |
| 2025-06-23 | You Angie | Buy | 1,403 | $9.43 | $13,230.29 | filing |
| 2025-06-23 | Piscitelli Dominic· Chief Financial Officer | Sale | 584 | $10.00 | $5,840.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.